Genetic Signatures Ltd
ASX:GSS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Genetic Signatures Ltd
ASX:GSS
|
AU |
|
Westone Information Industry Inc
SZSE:002268
|
CN |
Genetic Signatures Ltd
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
Revenue: Revenue for the first half of FY26 was $8.7 million, up $200,000 from the prior period.
Margins: Gross profit fell to $4.8 million and gross margin dropped to 55.7% from 58.8% due to higher input costs.
Operating Loss: Underlying operating loss improved to $6.4 million from $8.4 million in the previous half.
Cash Position: Cash and cash equivalents stood at $29.9 million at December 31, with current cash around $28 million.
Cost Review: The company is undertaking a detailed review of operating costs to address a high cash burn rate, with savings to be realized in FY27.
US Sales: US sales growth has been slower than anticipated, but two new US customers were added and engagement with large labs is ongoing.
AI Initiatives: The incoming CEO plans to use AI to streamline operations and accelerate revenue growth, focusing on both cost discipline and sales.
